Biomedical Research/Anti-aging research/rHGH, injection
Aging research
Pharmaceutical grade human growth hormone (HGH, injection)
Pharmaceutical grade IGF 1LR3(injection)
Pharmaceutical grade rhTPO (injection
Pharmaceutical grade Natural Galatamine (>98%, 50% purity)

Pharmaceutucal grade Recombinant Human Thrombopoietin (rhTPO, injection)


For medical research only

Not approved by FDA for human injection in USA

7500 IU/vial

wholesale package size: 100vial / package( 25cm X 25cm)

wholesale price list

Item # IU price per ug price FOB orange, CA 
TP7500 $295.00
TP1500 $399.00
TP5000 call
TP10,000 call
Retail price list
Item # IU price per ug price FOB  shipping*
TP75 $495.00
TP150 $717.00
TP500 call
TP1000 call
* plus $80.00 per shipment charge
Please e-mail us your question and request.

Endogenous thrombopoietin (TPO) is a cytokine which promotes platelet production by regulating growth and maturation of megakaryocztes, therefore increases the platelet level in the circulation. Nowadays the recombinant human thrombopoietin is preferred as agent of therapy for Thrombocytopenic purpura and radiation-induced or chemical-induced thrombocytopenia.
rhTPO is a full-length molecule identical to natural form. It is a single chain, composed of 353 amino acids and including 21 amino acids in the signal peptide. rhTPO is glycoprotein, its molecular size is 70-120KD.

The development of rhTPO was initiated in 1995 .The process of development and pre-clinical studies were completed at the end of 1998. The application for clinical trails was approved as new drug of Class I by State Drug and Food Administration (SFDA) of China In 1999. The whole clinical study (Phase I, II and III) has been already completed until May, 2003.
The human cDNA containing TPO ORF was cloned from fetal lung cDNA library. rhTPO was expressed in Chinese Hamster Ovary cell Line (CHO). Fermentation was carried out in a large-scale, continuous perfusion cell culture system using packed-bed bioreactors (Celligen Plus). To ensure high purity, rhTPO was purified by multi-step method. The overall recovery rate was 16-25%. The specific activity of rhTPO in bulk was 280,000 IU/mg. Impurity: Residual DNA (<100pg/50μg), Endotoxin (<10EU/50μg). Finally rhTPO was formulated with human serum albumin (HSA) and other additives in the environment of pH: 6.4-7.4. Aqua dose form, 50μg/Vial, stored at 2-8 Celsius degree.

The clinical study demonstrated that rhTPO was well tolerated by patients. It could accelerate the platelet recovery after radiotherapy or chemotherapy, decrease the requirement for platelet transfusion significantly. rhTPO was safe and effective in the treatment of radiation-induced or chemical-induced Thrombocytopenia. There was no influence of rhTPO on HB, WBC, the function of kidney or liver, no influence on platelet form, platelet aggregation function or coagulation. Only a few slight adverse events occurred during clinical study. Low titer of antibody was observed in a few patients, but it didn't have neutralizing ability.